Pegylated Interferons for the Treatment of Chronic Hepatitis C: Pharmacological and Clinical Differences between Peginterferon-α-2a and Peginterferon-α-2b

Author： Foster Graham R.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.70, Iss.2, 2010-01, pp. : 147-165

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Peginterferon-α2a in the treatment of chronic hepatitis C

By Akimov Sergey   Adeyemi Oluwatoyin M  

Future Virology, Vol. 1, Iss. 6, 2006-11 ,pp. : 689-701

Future Medicine

Access to resources Recommend Favorite

Peginterferon-α2a for the treatment of hepatitis B infection

By Cooksley W Graham E  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 8, 2005-07 ,pp. : 1373-1380

Informa Healthcare

Access to resources Recommend Favorite

Peginterferon-α2a (40 kDa) for chronic hepatitis C

By Hadziyannis Stephanos J   Papatheodoridis George V  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 4, 2003-04 ,pp. : 541-551

Informa Healthcare

Access to resources Recommend Favorite

Peginterferon-α-2a + ribavirin: shorter treatment duration inferior in hepatitis C

By  

Inpharma, Vol. 1, Iss. 1597, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Peginterferon-α-2b: Autoimmune hepatitis in a patient with chronic hepatitis C virus and HIV infections: case report

By  

Reactions Weekly, Vol. 1, Iss. 1230, 2008-01 ,pp. : 28-29

Adis International

Access to resources Recommend Favorite